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Neuropeptidea b s t r a c t
Profoundneuropeptide diversity characterizes the nematode nervous system, but it has proven challenging
tomatch neuropeptide G protein-coupled receptors (GPCR)with their cognate ligands in heterologous sys-
tems. We have expressed the Caenorhabditis elegans GPCR encoded in the locus T19F4.1, previously
matched with FMRFamide-like peptides encoded on the ﬂp-2 precursor gene, in mammalian cells and in
the yeast Saccharomyces cerevisiae. Pharmacological characterization revealed that the receptor is potently
activated byﬂp-2 peptides inCHO cells (10 nMEC50) and in yeast (100 nMEC50), signaling through aGqa
pathway in each system. The yeast GPCR expression system provides a robust assay for screening for
agonists of the ﬂp-2 receptor and is the target of an ongoing high-throughput screening exercise.
 2012 Australian Society for Parasitology. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
FMRFamide-like peptides (FLPs) are important neurotransmit-
ters and neuromodulators in invertebrates, including parasitic hel-
minths, arthropods and other organisms (Price and Greenberg,
1989; Greenberg and Price, 1992; Walker, 1992; Halton et al.,
1994; Shaw et al., 1996; Brownlee et al., 2000; Maule et al.,
2002). At present, nearly 80 distinct FLPs encoded on 34 ﬂps (pre-
cursor genes) have been predicted from the Caenorhabditis elegans
genome (McVeigh et al., 2005, 2006; Husson et al., 2007; Li and
Kim, 2008, 2010; Walker et al., 2009). Despite extensive bioinfor-
matic searches, all family members may not have been identiﬁed.
In addition to FLPs, 48 C. elegans neuropeptide-like protein (nlp)
genes have been identiﬁed, deﬁning almost 140 total putative neu-
ropeptides in this classiﬁcation (Nathoo et al., 2001; McVeigh et al.,
2006, 2008; Husson et al., 2007; Li and Kim, 2008, 2010), as well as40 precursor genes encoding insulin-like peptides (Li and Kim,
2008, 2010).
Approximately 60 genes encoding putative neuropeptide G
protein-coupled receptors (GPCRs) have been annotated in the C.
elegans genome (Bargmann, 1998; Keating et al., 2003). The num-
ber of putative ﬂp- and nlp-encoded neuropeptides is much higher
than the number of predicted neuropeptide GPCRs, implying that a
single receptor is likely to be activated by multiple peptides. In C.
elegans (Nathoo et al., 2001; McVeigh et al., 2005, 2006; Husson
et al., 2007; Li and Kim, 2008, 2010; McVeigh et al., 2008; Walker
et al., 2009) and other invertebrates (Bellés et al., 1999; Fujisawa
et al., 1999; Furukawa et al., 2001), multiple forms of related pep-
tides are typically encoded on one precursor protein gene and
these peptide families can recognize the same GPCR, as has been
shown for the Drosophila allatostatin type A receptor (Larsen
et al., 2001; Lenz et al., 2001) and as appears to be the case for
several FLP families analyzed in Ascaris suum physiological experi-
ments (see McVeigh et al., 2006). Since the publication of the C. ele-
gans genome in 1998 (Consortium, 1998), a relatively small
number of orphan C. elegans neuropeptide GPCRs has been
matched with a cognate ligand (see Lowery et al., 2003; McVeigh
et al., 2006; Husson et al., 2007). Although many orphan vertebrate
GPCRs have been paired with endogenous ligands using ap-
proaches employing heterologous receptor expression systems
and reverse pharmacology (Civelli et al., 2001), this approach has
not been uniformly straightforward for nematode neuropeptider-
gic GPCRs.
2 M.J. Larsen et al. / International Journal for Parasitology: Drugs and Drug Resistance 3 (2013) 1–7As part of a large-scale project devoted to identifying peptide-
receptor matches in C. elegans (Greenwood et al., 2005; Woods
et al., 2010), we identiﬁed the GPCR annotated as T19F4.1 as a
receptor for peptides encoded on the ﬂp-2 precursor gene (Lowery
et al., 2003). This ﬁnding was also reported by another group
(Mertens et al., 2005). We report here further characterization of
the pharmacology of this putative C. elegans GPCR with its cognate
ligands following expression in mammalian cells and in the yeast
Saccharomyces cerevisiae, which has proven useful for the heterol-
ogous expression of GPCRs and for high-throughput screening for
small molecule ligands of these receptors (Broach and Thorner,
1996; Pausch, 1997; Ladds et al., 2005; Minic et al., 2005; Wang
et al., 2006; Dowell and Brown, 2009; Geary, 2012; Geary and
Ubalijoro, 2012). This GPCR has been termed the FLP-2 receptor
(FLP-2R), because the receptor activating peptides are encoded
on the C. elegans precursor gene ﬂp-2 (Mertens et al., 2005).2. Materials and methods
2.1. Materials
Synthetic peptides were made at Auspep Pty. Ltd. (Parkville,
Australia) and Sheldon Biotechnology Center (McGill University).
Chinese hamster ovary cell line CHO-10001A (CHO cells), cell
culture media, transfection and assay reagents were as described
previously (Larsen et al., 2001; Kubiak et al., 2002). U-73122 (a
phospholipase C inhibitor) was obtained from the Pﬁzer com-
pound collection (Bleasdale et al., 1990). Yeast strains and vec-
tors (Wang et al., 2006) were obtained under license from
Cadus Corp.
2.2. Cloning and plasmid preparation
Molecular biological techniques followed either manufacturer’s
recommendations or general protocols. A variety of PCR primers
were designed using the coding sequence for locus T19F4.1 as pre-
dicted in Wormpep (release 13). Bioinformatic analyses of the C.
elegans genome using previously cloned C. elegans FLP GPCRs
(Kubiak et al., 2002, 2003) had identiﬁed this gene as a candidate
neuropeptide GPCR (not shown). The only signiﬁcant modiﬁcation
to the amplicon was the addition of an optimized translational ini-
tiation sequence immediately preceding the authentic initiation
codon (‘‘GCC GCC’’) (Kozak, 1987). Using cDNA prepared from C.
elegans strain N2 with sense and antisense primers deduced from
the C. elegans genome, PCR products encompassing the complete
open reading frame of T19F4.1 were cloned directly into the
eukaryotic expression vector pCR3.1 (Invitrogen, Carlsbad, CA).
Nucleotide sequence analysis by standard protocols revealed the
presence of 3 distinct clones, each in multiple copies (Fig. 1). The
longest of these was chosen for further analysis; this clone was
designated the Ce50b (ﬂp-2R)/pCR3.1 plasmid and the cDNA it en-
codes is identical to T19F4.1b (Lowery et al., 2003; Mertens et al.,
2005).
2.3. Cell culture, cell transfection and intracellular Ca2+ mobilization
assay
CHO cells were cultured and transfected essentially as de-
scribed previously (Kubiak et al., 2002, 2003) with some modiﬁ-
cations. The ﬂp-2R/pCR3.1 plasmid (5 lg DNA/10 cm plate) was
used for transfection with the LipofectAmine PLUS™ (Invitrogen,
Carlsbad, CA) method. The assay for functional expression em-
ployed a 96-well ﬂuorescence imaging plate reader (FLIPR)
(Molecular Devices, Sunnyvale, CA) essentially as described pre-
viously (Kubiak et al., 2002, 2003), exposing the transformedcells to 200 invertebrate neuropeptides (Kubiak et al., 2002).
In temperature shift experiments, transfected cells were split
and plated in 96-well FLIPR plates 24 h post transfection, fol-
lowed by an additional 24 h incubation at 37 C and then a
28 C incubation for 24 h prior to peptide testing. In some exper-
iments, the phospholipase C inhibitor U-73122 was added in
HBBS/HEPES/probenecid, 0.1% DMSO, 10 lM ﬁnal concentration,
10 min before the addition of peptide.2.4. Expression in yeast
The ORF from plasmid ﬂp-2R/pCR3.1 was subcloned into the
yeast vector Cp4258, which carries a LEU2 selectable marker (see
Wang et al., 2006) following PCR ampliﬁcation using 50- and 30- ter-
minal primers that generated an NcoI and an XbaI restriction site,
respectively, which were the cloning sites used in the vector. The
resultant ﬂp-2R-Cp4258 plasmid was transformed into Escherichia
coli for propagation using ampicillin selection and then trans-
formed into a collection of strains of S. cerevisiae based on
CY13193 (MATa PFUS1-HIS3 far1D1442 gpa1D1163 his3 leu2 lys2
trp1 ura3 sst2D2 ste14::trp1::LYS2 ste18c6-3841 ste3D1156
tbt1-1) as described previously (Wang et al., 2006; Kimber et al.,
2009). Each strain contains an integrated modiﬁed copy of the
yeast Ga-subunit gene (GPA1) that incorporates the terminal pen-
tapeptide sequences from the mammalian Gi-, G12-, G13-, Gz-, Gq-
and Gs-a proteins, in addition to others based on C. elegans G-a
proteins (gpa-1, gpa-2, gpa-7, gpa-9, gpa-12 and gpa-16), to facili-
tate the interaction between this protein and heterologous GPCRs.
It should be noted that the C-terminal pentapeptide is identical in
C. elegans and mammals for Gq (egl-30) and Gs (gsa-1). The yeast
strains express HIS3 under control of the FUS1 promoter when
an agonist activates the heterologously expressed GPCR. Thus, acti-
vation of FLP-2R by its peptide ligand leads to the correction of the
histidine auxotrophy, enabling growth in histidine-deﬁcient
medium.
Strains were cultured in Complete Minimal (CM) dropout
medium (Sigma–Aldrich, St. Louis, MO) and transformed using
the lithium acetate method (Gietz et al., 1995). Positive transfor-
mants were selected in plates with CM medium lacking leucine
(CM/Leu) and used for receptor activation assays in CM liquid
medium lacking leucine and histidine (CM/Leu/His), supple-
mented with 0.05 M MOPS, pH 6.8. Brieﬂy, a colony was grown
overnight in CM/Leu at 250 rpm and 30 C, cells were harvested
by centrifugation at 4000g for 1 min and rinsed thoroughly in
CM/Leu/His to eliminate histidine. Cell density was established
by absorbance at 600 nm and 3000 cells/well in CM/Leu/His
were seeded a 96-well plate to incubate with serial dilutions
of ﬂp-2 peptides. After 44 h incubation at 30 C, cell growth
was measured by Alamar Blue ﬂuorescence after 2–4 h of incu-
bation with 20 ll Alamar Blue (Sigma–Aldrich) at 30 C for color
development (Klein et al., 1997). Fluorescence was measured in
a Synergy H4 Hybrid Multi-Mode Microplate Reader (BioTek)
set at 560 nm excitation/590 nm emission. Experiments were
performed three times in three replicates using as controls
untransformed strains and transformants in presence of
histidine.2.5. Data analysis
Concentration–response curves for CHO cell and yeast experi-
ments were analyzed by nonlinear regression using Prism (Graph-
Pad Software, Inc. San Diego, CA) based on each treatment run in
triplicate and expressed as mean values ±95% conﬁdence intervals
(C.I.).
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Fig. 1. Alignment of predicted protein sequences of T19F4.1 and obtained clones. T19F4.1a and b correspond to the receptor sequences reported in WormPep and Ce50b, c
and d correspond to the clone sequences obtained from cDNA ampliﬁcation and cloning. The CLC sequence viewer was used to generate this multiple alignment in which
identical residues are represented by dots.
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3.1. Molecular cloning of T19F41/ﬂp-2R and phylogenetic analysis
Previous work described 2 alternatively spliced transcripts that
are encoded by the gene T19F41.1 (Mertens et al., 2005). PCR of C.
elegans cDNA recovered the longer of these transcripts
(T19F41.1b), which was used for the work in this paper. Two other
novel transcripts were also detected that are distinct in the
C-terminal region (Fig. 1). Examination of genomic sequence sug-
gested these transcripts were similarly generated via alternative
splicing. Previous phylogenetic analysis showed that this receptor
is grouped with other known and putative C. elegans neuropeptide
GPCRs, including C26F1.6, which is activated by relatively high con-
centrations of FLPs encoded on ﬂp-7 and ﬂp-11 (Mertens et al.,2004). The T19F41.1b cDNA was used for all experiments reported
here.
3.2. Receptor expression and identiﬁcation of cognate ligands for FLP-
2R in mammalian cells
The receptor-ligand matching was achieved by functionally
expressing FLP-2R in CHO cells in a transient transfection mode.
A Ca2+ mobilization assay was used to monitor receptor activation
by FLIPR in response to >200 synthetic peptides representing a
variety of C. elegans and other invertebrate FLPs. The expressed
receptor was activated in a concentration-dependent manner by
two peptides encoded on ﬂp-2, SPREPIRF-NH2 (FLP-2A) and
LRGEPLRF-NH2 (FLP-2B) (Fig. 2). Cells transfected with other inver-
tebrate GPCRs, or with the empty vector, did not respond to either





FLP2-A + U-73122 (10 µM)
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Fig. 2. Functional expression of FLP-2R/T19F4.1 in CHO cells; Ca2+ mobilization assay by FLIPR. (A) Activation of the receptor by FLP-2A (SPREPIRFa) was temperature-
independent. (B) FLP-2R was equally effectively activated by FLP-2A and FLP-2B (LRGEPIRFa) in cells cultivated at 37 C (EC50 values for the peptides were not statistically
different, p > 0.05). Pre-incubation with U-73122 prevented Ca2+ release in response to FLP-2A, indicating that FLP-2R is coupled to the Gqa signaling pathway.
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functional in transfected cells cultured either at 28 C or 37 C
(Fig. 2A). This is exempliﬁed by the responses to increasing concen-
trations of FLP-2A, with EC50 values and 95% conﬁdence limits of
18.5 nM (14.7–23.2 nM) and 7.7 nM (6.3–9.5 nM) under 28 C
and 37 C cell culture conditions, respectively. It can be concluded
that the FLP-2R receptor was slightly more functional at 37 C than
at 28 C (based on non-overlapping 95% conﬁdence limits).
The FLP-2A and FLP-2B peptides were equally potent in cells
cultured at 37 C with EC50 values and 95% CI of 3.5 nM (1.59–
7.6) and 6.5 nM (4.2–10.2), respectively (Fig. 2B). The ligand-
evoked Ca2+ signal was completely abolished in cells pretreated
with the phospholipase inhibitor U-73122 (Fig. 2B), suggesting
that the FLP-2 receptor couples to Gqa signaling pathways in these
cells.
3.3. FLP-2R functional expression in yeast
Expression of FLP-2R in S. cerevisiae generated a strain in which
growth in the absence of exogenous histidine in the medium was
only possible in the presence of a receptor agonist, such as either
of the FLP-2 peptides (Fig. 3). Growth in the presence of these pep-
tides only occurred in the S. cerevisiae strain that co-expresses the
Gqa chimera; no agonist-dependent growth (at the EC80 concentra-
tion for the Gqa chimera strain) was observed in yeast strains
expressing FLP2R and other Ga chimeras or in yeast transformedwith the empty vector or other invertebrate GPCRs, although all
these strains grew normally in the presence of histidine (data not
shown). In the Gqa chimera strain (CY13397), FLP-2A had an EC50
value and 95% CI of 71 (66–78) nM, with a corresponding value
of 127 (121–134) nM for FLP-2B (Fig. 3). None of the other tested
peptides had potency within a factor of 10 of FLP-2A or FLP-2B
(data not shown), suggesting again that FLP-2R is the most relevant
receptor for them.
4. Discussion
Analysis of the C. elegans genome has identiﬁed 60 genes
encoding predicted GPCRs that are likely to have peptide ligands
(Bargmann, 1998; Keating et al., 2003). Only a subset of these
receptors has been matched to a ligand (see Lowery et al., 2003;
McVeigh et al., 2006; Husson et al., 2007). Among them is
T19F4.1, reported as the FLP2 receptor (Lowery et al., 2003; Mer-
tens et al., 2005). As part of a large-scale program to match C. ele-
gans and Drosophila melanogaster putative peptide GPCRs with
their ligands for screen development (Larsen et al., 2001; Lowery
et al., 2003; Greenwood et al., 2005; Woods et al., 2010), our group
had also identiﬁed this receptor as being the target for peptides en-
coded on the ﬂp-2 precursor gene (Lowery et al., 2003). However,
in light of some differences in pharmacology apparent in compar-
ing the data from mammalian cell expression in two laboratories
and the expression of this invertebrate peptide GPCR in yeast in
Fig. 3. FLP-2R/T19F4.1 activation by FLP2 peptides in yeast. The peptides FLP2-A
(SPREPIRFa) and FLP2-B (LRGEPIRFa) activated T19F4.1 in a concentration-depen-
dent manner when the receptor is expressed in S. cerevisiae strain CY13397 which
co-expresses a chimeric Gaq protein. Receptor activation was quantiﬁed using an
Alamar Blue ﬂuorescence assay. Data were normalized to the highest value and
presented as the mean and SEM of three experiments (n = 3).
M.J. Larsen et al. / International Journal for Parasitology: Drugs and Drug Resistance 3 (2013) 1–7 5a format suitable for use in high-throughput screening (Geary,
2012; Geary and Ubalijoro, 2012), publication of the current data
is warranted.
The most pronounced difference in the two sets of experiments
on expression of FLP-2R in mammalian cells is the difference in po-
tency observed. In the work of (Mertens et al., 2005), peptide FLP2-
A activated the FLP-2R with EC50 values in the high nanomolar
range, while the FLP2-B peptide was active only at micromolar
concentration and did not saturate the receptor even at 100 lM.
In contrast, we found both peptides to be roughly equipotent, with
EC50 values in the range of 5 nM for FLP-2R expressed in mamma-
lian cells (Fig. 2B). These differences in FLP-2R pharmacology might
be due to the use of different cells for expression, which were CHO-
10001A cells in the current studies and CHO-K1 cells in (Mertens
et al., 2005). Potency values in the nM range are more consistent
with many other peptide-GPCR systems, including examples from
C. elegans (Kubiak et al., 2003, 2007; McVeigh et al., 2006). The
potencies reported in the current work are also more consistent
with the physiological effects of the ﬂp-2 peptides on nematode
(Ascaris suum) muscle physiology; FLP-2A and B had concentra-
tion-dependent excitatory effects on dorsal and ventral muscle
strips of A. suum. The activity thresholds for these peptides were
10 nM (LRGEPIRFamide) and 3 nM (SPREPIRFamide) (Geary,
unpublished observations). The ﬂp-2-encoded peptides were also
active in bioassays using the A. suum ovijector (Moffett et al.,
2003) and C. elegans pharynx (Papaioannou et al., 2005); again, re-
sponses were observed at concentrations as low as 10 nM in these
studies. That the current data reveal the same level of potency for
biological activity of these peptides and activation of FLP-2R ex-
pressed in mammalian cells adds conﬁrmation that this is likely
to be the physiologically relevant pairing.
Based on pharmacological evidence with a phospholipase inhib-
itor, we conclude that FLP-2R signals through the Gqa pathway in
CHO cells. This association was conﬁrmed in the yeast system;
FLP2-induced growth of recombinant yeast expressing FLP-2R
was only observed in strains that also expressed the Gqa chimeric
construct. Conservation of the signaling pathway suggests that the
function of the receptor-G protein interaction is maintained in two
vastly different heterologous systems, but does not prove that this
interaction is also operative in situ. Null mutations in the Gqa locus
(EGL-30) are apparently lethal in C. elegans, while reduction-
in-function alleles have severe paralytic and other consequences
(Bastiani and Mendel, 2006), implicating function of this G protein
in multiple pathways. This subunit mediates the signaling pathwayfor an excitatory C. elegans FLP, FLP17A (KSAFVRFamide) (Papa-
ioannou et al., 2008), but evidence is not yet available to link it
with the actions of the FLP2 peptides in C. elegans.
Expression of ﬂp-2 in C. elegans has been traced to two neurons
involved in amphidial circuits, additional neurons in the pharyn-
geal region, a neuron in the ventral ganglion and a motorneuron
that innervates dorsal somatic muscle (Kim and Li, 2004). The tis-
sue localization of the FLP-2R encoded in the T19F4.1 locus has not
been reported in this organism, but would add important and rel-
evant information to the biology of this neuropeptidergic system.
Inferences about the utility of various proteins as targets for
anthelmintic discovery are often based on phenotypic observations
of loss-of-function mutations in the genes encoding the protein or
as a result of RNA interference-mediate reduction in mRNA (McC-
arter, 2004; Behm et al., 2005; Geary, 2012). In that regard, it has
been reported that knockdown of the ﬂp-2 gene in the C. elegans
rrf-3 strain resulted in embryonic lethality or larval arrest and
post-embryonic growth defects (Mousley et al., 2010). However,
RNA interference experiments conducted in an rrf-3 strain on 60
putative GPCRs encoded in the C. elegans genome did not reveal a
reported phenotype for T19F4.1 (Keating et al., 2003). In general,
neuropeptide systems seem not to be constantly activated, so that
antagonists (or RNA interference or loss-of-function mutations)
may often be difﬁcult to detect. These kinds of data, coupled with
the potent and profound effects of many FLPs on nematode neuro-
muscular function (McVeigh et al., 2005), suggest that standard
validation of drug targets by inactivation may not necessarily to
support FLP receptors as useful proteins for therapeutic interven-
tion in human or animal parasites. We postulate that agonists
are more likely to be useful for chemotherapy (Geary, 2012; Geary
and Ubalijoro, 2012). However, it must also be acknowledged that
signiﬁcant phenotypes can be derived from RNAi of ﬂp-ergic sys-
tems in plant parasitic nematodes (Dalzell et al., 2010), and better
phenotypic assays in other kinds of nematodes may be expected to
motivate searches for FLP-GPCR antagonists (see Dalzell et al.,
2012).
The yeast system for functional expression of heterologous
GPCRs is well suited to screening for GPCR agonists (Broach and
Thorner, 1996; Pausch, 1997; Ladds et al., 2005; Minic et al.,
2005; Wang et al., 2006; Dowell and Brown, 2009). This system
is built around the fact that yeast express a peptide GPCR for which
the physiological ligand is the mating pheromone (Wang et al.,
2006; Dowell and Brown, 2009). The engineered yeast strains have
null mutations in the genes encoding the endogenous GPCR, the
endogenous Ga subunit and in elements that serve to desensitize
the signaling cascade. These modiﬁcations enable heterologous
GPCRs to be expressed in isolation with co-expression of Ga chi-
meras that help to establish receptor-G protein coupling (Brown
et al., 2000; Wang et al., 2006; Dowell and Brown, 2009). In this
system, receptor activation can be coupled to a reporter gene; we
chose to use a HIS3 reporter, which corrects an auxotrophy. Thus,
activation of the nematode GPCR permits growth of the yeast
strain on histidine-deﬁcient medium. This system allowed us to
conﬁrm the ligand match for FLP-2R observed in CHO cells.
Although the potency of the peptide ligands was signiﬁcantly low-
er in yeast than in mammalian cells, this may simply reﬂect the
barrier properties of the yeast cell wall, which restrict diffusion
of large, charged molecules such as peptides to the cell membrane
(the location of the GPCR). The lower potency of the FLP2 in yeast
compared to mammalian cells is consistent with results in other
nematode GPCR-peptide pairs in this recombinant yeast system
(unpublished observations).
An attractive feature of the recombinant yeast system is its
robustness, supporting the potential use of such strains for screen-
ing chemical libraries for non-peptide FLP receptor ligands as po-
tential anthelmintics. This feature is particularly valuable for
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Ubalijoro, 2012). Screening for agonists relies on the detection of
growth, as evidence by a change in color or ﬂuorescence, against
a null background. Detection of growth, as opposed to inhibition
of growth, requires minimal statistical analysis; any change above
background is of interest. The system also permits co-incubation of
multiple strains of yeast with different receptors (‘multiplex’ for-
mat); growth of any strain induced by an agonist is not affected
by the presence of cells expressing other receptors, and the target
of the agonist can be determined in follow-up assays using the
component strains in separate wells. This format also means that
the inoculum size can be imprecise and that the time of incubation
can vary; both factors are important considerations in laboratories
which may not be fully equipped and to which travel may not al-
ways be reliable. The ability to grow yeast at ambient tempera-
tures, to detect changes in Alamar blue color visually, and the
robustness of the yeast system led to the implementation of a
screening project for non-peptide ligands of FLP receptors as candi-
date anthelmintics (Geary, 2012; Geary and Ubalijoro, 2012). Based
on the physiological activity of FLP2 peptides and the qualities of
the FLP-2R yeast strain, this target has been incorporated in the
multiplex system.
Concerns about the conservation of pharmacological character-
istics for receptors expressed in heterologous systems may be rel-
evant. In that regard, it is reassuring that there is experimental
evidence to suggest that the ligand-binding proﬁle of GPCRs is
maintained whether the receptor is expressed in yeast or mamma-
lian cells (Brown et al., 2011). Whether this will be true for nema-
tode GPCRs remains to be proven.
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